Sarcoma Biopsy Market to Surpass US$ 247.47 Million by 2027

Global Sarcoma Biopsy Market, by Product Type (Reusable Device and Disposable Devices), by End User (Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 192.55  million in 2019, and is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Global sarcoma biopsy market is expected to witness to significant growth during the forecast period, owing to increasing technological advancements in the field of biopsy. For instance, in November 2015, Cook Medical launched its new EchoTip ProCore 20 gage needle with ReCoil Stylet, which will help the physicians to collect the blood samples from the rom difficult anatomical locations. Ecotip ProCore has core-trap technology, which will allow the physicians to collect samples during the minimally invasive procedure.

Furthermore, in October 2017, European Commission approved the acquisition of C.R Bard by Becton Dickinson Company. This acquisition helped the company to manufacture new medical devices and technology, which will be utilized to cure many serious conditions such as cancer.

Browse 26 Market Data Tables and 25 Figures spread through 151 Pages and in-depth TOC on Global Sarcoma Biopsy Market, by Product Type (Reusable Device and Disposable Devices), by End User (Hospitals, Ambulatory Surgical Centers, and Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"

To know the latest trends and insights related to Global Sarcoma Biopsy Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/sarcoma-biopsy-market-3819

Key Takeaways of the Global Sarcoma Biopsy Market:

• The global sarcoma Biopsy market is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027), owing to increasing technological advancements in the field of biopsy.
• Kaposi sarcoma being one of the sarcoma condition is much more common among men than women, and is rarely observed among children. For instance, according to the American Cancer Society (ACS), February 2016 data findings, around 1 in 200 transplant patients in the U.S. suffer from Kaposi sarcoma. In the U.S.
• Major players operating in the global sarcoma biopsy market include R. Bard, Inc., Becton, Dickinson and Company, Argon Medical Devices, InVivo Therapeutics Corporation, Cook Medical Incorporated, UROMED, and Sterylab